RxDoctor Payments Data

Sevan Sagherian

Medical · Philadelphia, PANPI 1790253300

Payments from drug & device makers

$1,374in general payments, 2019–2025

Across 15 payments — averaging $91.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$263
  • Novo Nordisk$220
  • Insulet Corporation$150
  • Cequr Corporation$150
  • Abbott$133
  • Medtronic$122
  • plus $336 from 4 others

What the payments were for

  • Food & beverage$1,374100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,374 in reported general payments places this provider in the 70th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$2,436
Medicare patients
33
Services billed
63

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide823$844,382
JardianceEmpagliflozin603$518,452
OzempicSemaglutide499$493,298
MounjaroTirzepatide234$241,296
FarxigaDapagliflozin Propanediol225$189,156
JanuviaSitagliptin Phosphate136$128,497
Lantus SolostarInsulin Glargine,hum.Rec.Anlog538$59,507
TradjentaLinagliptin95$52,293
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog56$49,796
Insulin Lispro Kwikpen U-100Insulin Lispro190$38,454
Novolog FlexpenInsulin Aspart170$38,293
Humalog Kwikpen U-100Insulin Lispro156$35,736
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog70$32,217
Humalog Kwikpen U-200Insulin Lispro18$29,631
Gvoke Hypopen 2-PackGlucagon47$28,181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Baqsimi$109$1,089,5951,071 claims
Novo NordiskOzempic, Xultophy 100-3.6$220$511,278513 claims
AstraZenecaFarxiga$110$189,156225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,594 medical providers in Pennsylvania.

Other medical in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →